Biotech

All Articles

' Professional intuitiveness' led FDA specialists to back Zevra's rare disease med

.Zevra Therapies' rare illness medicine seems to be on the path to confirmation this autumn after ac...

Pfizer takes $230M hit after axing failed DMD gene therapy

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) genetics therapy failing has actually gone a $23...

AC Immune observes 'spots' potential in Alzheimer's medicine information

.After greater than two decades of deal with neurodegenerative health conditions, Swiss biotech AC I...

GSK loses ph. 2 HPV vaccination over shortage of best-in-class potential

.GSK has junked a phase 2 human papillomavirus (HPV) vaccine from its own pipe after deciding the re...

OS Treatments refiles $6M IPO to money HER2 medication, preclinical ADCs

.OS Therapies will certainly provide on the NYSE American inventory exchange today using a $6.4 mill...

ALX's waning CD47 feedback price sends stock spiraling down

.ALX Oncology's phase 2 stomach cancer cells feedback cost has diminished. After seeing its CD47 blo...

Ionis axes eye health condition coming from aim ats of Roche-partnered possibility after data dissatisfy

.One More of Ionis Pharmaceuticals' crucial midphase readouts has disappointed expectations, motivat...

Biogen's chief executive officer mentioned no unsafe deals in 2023. He's ready to be daring

.While Biogen's pharma peers are hunting for late-stage resources with little threat, chief executiv...

Instil refills pipe in $2B biobucks cope with ImmunOnco

.Instil Bio has been a biotech seeking a pipe after it ditched its own lead properties over the fina...

Biogen ignores Denali Alzheimer's collab

.Biogen has returned legal rights to a very early Alzheimer's illness plan to Denali Rehabs, going o...